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Summary: Behufs disease is characterized by orogenital ulccrations and ocular lesions, Other features include
arthritis, thrombophlebitis, neurological abnormalities and skin lesions. The disease is characterized by a relapsing
inflammatory process of unknown aetiology. Lipoprolcin(a) is an LDL-likc particle with a large glycoprotein called
apolipoprotein(a) attached to its npolipoprotcin B moiety through one or more clisulphidc bonds. Apolipoprotein(a)
is related to plasminogcn from which the cn/yme plasmin, that hydrolyscs fibrin blood clots, is released by tissue
plasininogcn activators. The unique structural features of Lp(a) give it the potential for atherogenie and thrombo-
genic activities. In the present study 35% of patients with /icj//(.'t'/\s disease were shown to have higher Lp(a)
concentrations than the cut-off point (0.30 g/l) for atherosclerosis. Plasma Lp(a) concentrations in the remission
period were also found 1ο be lower than during the active period in the same patients (23% decreased). Lp(a)
showed significant correlations with acute phase rcaclanls such as crythrocyte sedimentation rate, polymorphonu-
clcar leukocytes and polymoφhonuclear leukocyte elastase activity. Therefore, it was concluded that the fluclations
of plasma Lp(a) levels with the activity of disease may be a contributing risk factor in the development of (hrombo-
gcnic complications in patients with Belief $ disease.
In conclusion, we suggest that plasma Lp(a) concentrations be determined for patients with Belter* disease, and
that patients wi th high Lp(a) levels be kept under close controls especially during the active period of the disease,
and taken into remission as soon as possible.
Introduction development of thrombotic events in Beh^efs disease is
. . . . . . ,. ι ι rv // / · n / , thought to be association of defective fibrinolysis (6).Behcet $ disease was discovered by Dr. Hulmi Behc.et ^Λ to .. , ,, . , . , „ , . , ,
.
 1IV5- , · ι ι · Λ ι ι ι - « I I Many studies have indicated that reduced hbnno ysisin 1937 and is characterized by oral and genital ulcers * , , J,
. .
 Λ .. ί{^ f^\ r « · ι ι Η · may be related to decreased endothehal cell productionand eye inflammation (1). Other features include artlin- * . . // , , , ,... 1 - 1 1 ι · , · ι ol tissue ρ asmmogen activator a n d increased concentra-tis, thrombophlebitis, neurological abnormalities and . . ; , & . . . „ ,
skin lesions (2). The disease aflbcts the arteries and Uo" of I.HHUC pln»mmogen aetivalor inhibiioi^l m pa-
veins. Tl,e predominant l,is«opathological lesion is a vas- ^^' /Jc//'f' '*«*>!* (,6' 7)" Ί hc clum8c oi cnd°-
culi.is with the vessel walls and perivascular «issues in- ""-''I'1 f11 m°(ha1cd Ρ~«««ιοη and release clue to vas-
mtnuxl mainly by lymphocytes but also by monocytes, f"1'1«5 dnmaoc 1!? rePortcd to bc 1>clalod Io dls'asc actlv'
plasma cells and neutrophils (3, 4). Thrombosis is one ' ^
of the vascular manifestations and is seen in about one Lipoprotein(a) [Lp(a)] described by I3et\\> in 1963 const!·
third of the patients (5), The basis of thrombosis in the tutcs a newly recognised cardiovascular risk factor with
patients is unclear. One of the factors responsible for implications in atherogenie and thrombogcnic processes
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(8). The protein moiety of human Lp(a) is composed of
apolipoprotein B10o and the unique, highly glycosylated
glycoprotein apolipoprotein(a), which is heterogeneous
in size. The two protein moieties are linked by disul-
phide bridges. The apolipoprotein(a) gene is highly ho-
mologous to plasminogen and contains multiple repeats
of a kringle 4 motif. Apolipoprotein(a) exhibits a strik-
ing size polymorphism, with the apolipoprotein(a) iso-
proteins ranging in size from Mr 420000 to 840000.
Inherited in an autosomal codominant fashion, the apoli-
poprotein(a) isoprotein is an important factor in deter-
mining plasma Lp(a) concentration, with an inverse cor-
relation between the size of the apolipoprotein(a) iso-
protein and the plasma Lp(a) concentration (9, 10). Due
to the striking similarity of apolipoprotein(a) to plasmin-
ogen, Lp(a) was suggested to act as an interloper in the
fibrinolytic system by competing with plasminogen for
its binding sites in a dose-dependent manner and inhibit-
ing plasminogen activation (11, 12). Therefore, elevated
plasma Lp(a) levels favour receptor occupancy by the
lipoprotein particle and are associated with an increased
thrombotic risk. It was reported that plasma Lp(a) levels
are influenced by activity of diseases such as myocardial
infarction, and by before and after surgical operation,
but are hardly affected by diet, age, sex or treatment
with lipid-lowering drugs (13 — 14).
In view of the above mentioned data, we have suggested
that high Lp(a) levels in patients with Behgefs disease
may be a contributing risk factor for the development of
thrombotic events (15). In the present study, we aimed
to conform our previous data on the expanded patient
group and to clarify the relationship of Lp(a) levels with
the disease activity.
leukocyte count, erythrocyte sedimentation rate were determined
immediately in one aliquot. The second aliquot and blood sample
without anticoagulant, that were allowed to clot for l h at room
temperature, were centrifiiged at 1500 g for 15 min immediately to
obtain plasma or serum samples. The serum samples were divided
into two aliquots. One was used for determinations of lipids, lipo-
proteins and protein electrophoresis. The other serum samples for
Lp(a) measurements and plasma samples for polymorphonuclear
leukocyte elastase measurement were stored at -70 °C until the
time of analysis within 3 months. .
 f
Serum cholesterol was measured by a cholesterol oxidase enzy-
matic method, triacylglycerols by a glycerol oxidase enzymatic
method, HDL-cholesterol by a cholesterol oxidase enzymatic
method in supernatant after precipitation with phosphotungstic
acid-MgC!2 and apolipoprotein A-I and B by a turbidimetric
immunoassay method [Sera-Pak Immuno Apo AI (Code no:
6821)/Αρο Β (Code no: 6822), Ames, Canada]. All determinations
including immunoassays were carried put by autoanalyzer (Techni-
con Axon). LDL-cholesterol was calculated by Friedewald formula
(17). Serum Lp(a) was measured using a commercial anti-apolipo-
protein(a) polyclonal capture enzyme-linked immunosorbent assay
called TintElize lipoprotein(a) (Catalog no: 610220; Biopool AB,
Umea, Sweden) according to the instruction sheet of manufacturer.
Using the above described method of analysis for Lp(a), intra-assay
coefficients of variation of 5.6 and 6.1 percent were obtained at
the 0.310 and 0.60 g/i of Lp(a) (n = 10), respectively.
Polymorphonuclear leukocyte elastase was determined by a rapid
homogenous imm noactivation (IMAC) assay, using monospecific
polyclonal antibodies directed solely against polymorphpnuclear
leukocyte elastase (18). Test kit was purchased from Merck (D-
64271 Darmstadt) (cat no.: 113322). Within-run CV% at 52 μg/l
(control plasma) was estimated as 5.2 (n = 10). Polymorphonu-
clear leukocytes (granulocytes) were counted by an automated
blood counter (MaxM, Coulter), erythrocyte sedimentation rate was
determined by classical Westergren method, serum a2-globulins by
protein electrophoresis (Helena Lab).
Plasma concentration of the lipids, lipoproteins and acute phase
reactants in the patients and in the controls were compared by the
Mann-Wliitney U test or Student's t test. Relationships among vari-
ables have been assessed by means of Pearson^ product-moment
(r) correlation coefficients. Wilcoxon test was used to compare the
results in the active and inactive periods of the disease.
Materials and Methods
The study group included 45 patients with Behget's disease (male
24 and female 21) with a mean age of 30.8 (age range: 17-55) and
40 healthy volunteers (male 20 and female 20) with a mean age of
31.1 (age range: 17-52). The patient group had a mean body mass
index (body weight in kg/squared height in m = kg/m2 height) of
22.8 ± 5.1 (mean ± SD) which was similar to that of the control
group of 23.4 ± 3.9. All the patients were diagnosed separately by
the Internal Medicine, Dermatology and Ophthalmology Depart-
ments. The diagnosis ofBehgefs disease was made according to the
criteria from the International Study Group for Beh$efs disease (16).
The disease activity was evaluated by physical manifestations such
as oral aphthous, genital ulcerations, uveitis and vasculitis and ap-
propriate laboratory investigations such as erythrocyte sedimenta-
tion rate, polymorphonuclear leukocytes count, polymorphonuclear
leukocyte elastase and a2-globulins. Six of the patients had throm-
botic complications such as superficial thrombophlebitis, which had
superimposed segmental thrombosis areas, laying on the veins of
lower extremity. At the time of the study, the patients were receiving
neither steroids nor lipid-lowering drugs.
Blood samples of 2.5 ml were drawn in collection tubes with
EDTA (1 g/1) anticoagulant and of 5 ml in tubes without anticoagu-
lant in the morning by venipuncture after an overnight fast. Antico-
agulated blood was divided into two aliquots. Polymorphonuclear
Results
The distribution and concentrations of serum Lp(a) in
patients with Behfefs disease and in control subjects are
shown in table 1 and figure 1. Plasma Lp(a) concentra-
tions in the patients were significantly higher than those
of control group (p < 0.05). Plasma Lp(a) concentra-
tions in patients with Behcefs disease were found to be
approximately equal to the cut-off point (0.300 g/1) for
a two-fold risk for athefothrombosis (19) and higher
than the cut-off point (0.18 g/1) for a twenty-one-fold
risk of cerebrovascular disease (20). According to figure
1, Lp(a) levels of sixteen patients (35%) and six control
subjects (15%) were found to be higher than the cut-off
point for atherosclerosis. Lp(a) levels were significantly
correlated with apolipoprotein B, polymorphonuclear
leukocyte and polymorphonuclear leukocyte elastase
levels (r = 0.52, p < 0.01; r = 0.39, p < 0.05; r = 0.36,
p < 0.05; respectively). The mean serum apolipoprotein
A-la level was significantly lower than in the controls
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Tab. 1 Lipids, lipoprotcins and some acute phase reaotants in patients with Belief's disease and
in control group.
Analytes
Lipoprotein(a), (g/1)
Mean ± SD
Median
Range
Apolipoprotein A-l (g/1)
Apolipoprotein B (g/l)
Total cholesterol (mmol/1)
Triacylglycerols (mmol/1)
HDL-cholesterol (mmol/1)
LDL-cholesterol (mmol/1)
Erythrocyte sedimentation rate (mm/h)
a2-Globulins (%)
PMN Leukocytes (106/1)
PMN Leukocyte elastasc ^g/l)
Controls
(n = 40)
(mean ± SD)
0.189
0.141
0.02
1.22
0.71
4.73
1.51
1.37
2.78
14.7
11. 1
3.1
44
±
-
-1-
-H
-J-
±
±
±
±
±
jh
Hh
0.115
0.49
0.21
0.17
0.88
0.47
0.18
0.80
1.6
1.8
0.6
19
Patients
(n = 45)
(mean ± SD)
0.312 ±
0.184
0.0 1 -
1.11 ±
0.92 ±
4.96 ±
1.14 ±
1.19 ±
3.22 ±
32.5 ±
13.6 ±
5.7 ±
244 ±
0.300
1.03
0.21
0.20
0.93
0.37
0.12
0.88
4.8
2.2
1.0
126
P
<0.05#
<0.05*
<O.OOI*
NS
<0.05*
<0.001*
<0.05*
<0.0l*
<0.0i*
<0.01*
<0.001#
Φ According to Mann Whitney U test * According to Student's "t" test NS: Not significant
(p < 0.05). Serum apolipoprotein A-I levels were signif-
icantly correlated with HDL-cholesterol levels in the pa-
tients (r = 0.36, p < 0.05). The mean serum apolipo-
protein B level of the patients was significantly higher
than that of the control group (p < 0.001). Also, triacyl-
glycerols, HDL-cholesterol and LDL-cholesterol levels
in the patients showed significant differences from those
of the control group apart from total cholesterol levels.
Other quantities related to the activity of disease in the
patients were found to be significantly higher than those
of control subjects (tab. 1). The quantities of the patients
with thrombotic complications are shown in table 2.
Lp(a) and other in these patients were found to be signif-
icantly different from the control subjects.
00
Healthy control Behcet's disease
Fig. 1 Serum Lp(a) concentrations in patients with Beh^et's dis-
ease and in controls. (Θ shows controls and Δ shows patients with
Behfefs disease, the dashed lines show the cut-off point for athero-
sclerosis).
Repeated measurements of the Lp(a) and other quanti-
ties were made in 10 patients while their disease was
active or inactive (tab. 3). During the period of active
disease, the mean concentration of Lp(a) was 0.326 g/I
and a significantly decreased mean value of 0.250 g/1
was obtained when the disease was inactive. Polymor-
phonuclear leukocytes, polymorphonuclear leukocyte
elastase, a2-globulins and erythrocyte sedimentation rate
showed significant differences between the active and
inactive periods of the disease (p < 0.01). Plasma con-
centrations of apolipoprotein A-I and HDL-cholesterol
were lower, and apolipoprotein Β concentration was
higher when the disease was active (data not shown).
Discussion
Plasma Lp(a) levels, which are under genetic control,
were highly skewed in the different ethnic groups. It has
been reported that the mean Lp(a) value of the Turkish
population (0.213 g/1) had a value near to the cut-off
point (0.30 g/1) for atheroslcerosis (21). Also, Beliefs
disease is most common in the east part of the Mediter-
ranean. The prevalence of the disease is reported to be
8/10000 in Turkey (22). It is well known that high
plasma Lp(a) level is associated with an increased inci-
dence of cardiovascular and cerebrovascular disease be-
cause of its thrombogenic and atherogenic effects. On
the endothelial surface, high plasma levels of Lp(a) can
interfere with the process of plasminogen-plasmin con-
version and result in decreased generation of plasmin
and attenuation of clot lysis (23). Moreover, recent re-
ports showed that Lp(a) has a direct action on endothe-
lial function and induces the production of tissue plas-
minogen activator inhibitor by endothelium cells (24).
Thus, high Lp(a) levels may have an association with
Eur J Clin Chem Clin Biochem 1995; 33 (No 8)
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Tab. 2 Anthropometric and analytical quantities of the patients with thrombotic complications
Patients
E.V.
Υ. Κ.
Μ. Κ.
F. G.
S.S.
1. Μ:
Mean
Median
Range
Control Group
Mean
Median
Range
Sex Age *
(a)
<J 27
<J 37
<J 32
<J 44
9 28
$ 42
Lp(a)
(g/1)
1.03
0.63
0.38
0.33
0.22
0.23
0.46**
0.33
0.22-1.03
0.18
0.14
0.02-0.55
PMN
Leukocytes
(109/1)
5.7
5.8
5.0
5.2
4.4
5.0
5.2*
5.0
4.4-5.7
3.1
2.9
1.8-4.6
Erythrocyte
sedimentation
rate
(mm/h)
40
25
35
32
31
38
33.5*
32.0
25-40
14.7
12.5
7-25
PMN
Leukocyte
elastase
320
288
210 ,
240
178
218
242**
218
178-320
44
34
21- 67
(X2-Globulin
13.4
12.8
13.3
12.9
12.5
13.2
13.5*
12.9
12.5-13.4
11.1
11.2
10.4-12.9
According to Mann-Wlntney U test * p < 0.05, ** p < 0.01
Tab. 3 Concentration of Lp(a) and some acute phase reactants in patients in active and inactive periods
in Behgefs disease.
Patients
1. . S.
2. T. .
3. S. K.
4. Ν. ς.
5. Υ. Κ.
6. E. S.
7. Α. K.
8. A. M.
9. M. K.
10. L M.
Medi n
Mean
p*<
Lp(a)
(g/D
active
period
0.197
0.124
0.521
0.138
0.637
0.121
0.756
0.151
0.388
0.235
0.216
0.326
0.01
PMN Leukocytes
inactive
period
0.106
0.082
0.387
0.092
0.551
0.057
0.627
0.143
0.279
0.207
0.174
0.251
(109/1)
active
period
5.1
4.7
5.5
4.9
5.8
4.7
6.2
4.7
5.0
5.8
5.2
0.01
inactive
period
2.9
3.1
3.6
2.6
3.1
2.5
4.6
2.5
3.1
3.2
3.0
Erythrocyte
sedimentation rate
(mm/h)
active
period
21
32
28
26
25
26
36
40
35
32
31
0.01
inactive
period
18
21
22
20
19
16
18
27
22
18
20
PMN
Leukocyte elastase
(μ§/0
active
period
263
198
273
235
288
180
340
160
210
250
239
0.001
inactive
period
168
110
165
167
140
120
210
110
98
124
141.
a2-Globulins
(%)
active
period
12.8
13.4
13.0
12.8
12.8
13.1
13.6
13.6
13.3
13.2
13.1
0.05
inactive
period
12.4
12.6
12.6
12.2
12.3#
12.4
13.1
13.1
12.5#
12.7#
12.5
According to Wilcoxon test # The patients with thrombotic complications
decreased fibrinolysis and increased tendency to throm-
bosis. The basis of thrombotic risk of Behgefs disease
is not yet understood. On the other hand, it was reported
that the reduced fibrinolytic activity caused by de-
creased production of tissue plasminogen activator and
its increased production by endothelium due to vascular
damage may contribute to thrombotic events in the pa-
tients (3, 6). The mean Lp(a) level (0.312 g/1) in patients
with Behfefs disease was found to be similar to the
cut-off point. The mean Lp(a) level of the patients with
thrombotic complications was found to be higher than
that of the control group (tab. 2). We believe that the
cutoff point of Lp(a) for atherogenesis differs in the vari-
ous ethnic groups because of the many factors affecting
atherogenesis (25) as well as the methodology and stan-
dardization problems of Lp(a) measurement. The
thrombotic effect of Lp(a) via its apolipoprotein(a) part
is dose-dependent because of competitive inhibition
with plasminogen (11, 12). Therefore, Lp(a) may be
more important for its thrombotic properties in Behfefs
disease since thrombotic events are more common than
atherosclerosis in the disease. Sixteen subjects (35.5%)
among the patients with Behfet's disease had values
higher than the cut-off point, and may therefore be at a
much greater risk for thrombo-atherogenesis.
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It has been previously reported that the thrombotic ten-
dency and the abnormal fibrinolysis is related to the dis-
ease activity (6). Also, Lp(a) is known as an acute phase
protein and is significantly correlated with acute phase
reactants (13, 14). The change of plasma Lp(a) concen-
tration was confirmed by the present study in patients
with Behgefs disease. Plasma Lp(a) levels in patients
with inactive Behfefs disease were found to be de-
creased by about 23% when compared to the active
period of disease. The fluctuations of plasma Lp(a)
levels with the activity of the disease may be a contrib-
uting risk factor for thrombogenesis in the active period
of the disease. There is no effective lipid-lowering drug
for Lp(a), the treatment of the active Behfet's patients
by appropriate drugs for Behfet's disease may play an
important role in lowering the plasma Lp(a) concentra-
tion.
Elastase is primarily located in the azurophil granules
and is an active component of the phagocytic system
of polymorphonuclear leukocytes (26, 27). Perivascular
infiltration of polymorphonuclear leukocytes in Behfefs
patients is well known. High plasma polymorphonuclear
leukocyte elastase levels, which are more specific than
erythrocyte sedimentation rate and a2-globulins, may
represent the activity of vasculitis in patients (28). Posi-
tive correlations between plasma Lp(a) and polymor-
phonuclear leukocyte elastase indicate that effects of
Lp(a) on development of thrombotic complications may
be related to the activity of the disease. Moreover, Lp(a)
has an independent effect on the decreased fibrinolysis
in patients, and it is also associated with disturbed endo-
thelial functions due to vasculitis.
The decreased concentrations of apolipoprotein A-I,
HDL-cholesterol and triacylglycerols found in the pa-
tients agree with previous findings (29, 30). High apoli-
poprotein B levels in patients could be explained by the
fact that apolipoprotein B presents chiefly in LDL and
Lp(a).
In conclusion, we suggest that plasma Lp(a) concentra-
tions be determined for patients with Behfefs disease,
and the patients with high Lp(a) levels be kept under
close control, especially during the active period of the
disease, and taken into remission as soon as possible.
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